Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.47 |
| ▸ | F9 | P00740 | 6/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395988 | 1.00 | F10 (0.47) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6396617 | 0.90 | F10 (0.53) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6396620 | 0.90 | F10 (0.53) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL5698259 | 0.89 | KLKB1 (0.37) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6393598 | 0.85 | F10 (0.51) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6393601 | 0.85 | F10 (0.51) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6390086 | 0.81 | F10 (0.53) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6392007 | 0.80 | F10 (0.51) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL6390740 | 0.79 | F10 (0.59) | F10F9F2PRSS1PRSS2 | |
| SCHEMBL5698226 | 0.79 | F10 (0.41) | F10F9F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203127-A1 | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | MERCK PATENT GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050203127-A1 | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | MERCK PATENT GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203127-A1 | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | F11, F12, F2 | F10 9/4885F9 5/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.